Gynecologic Cancer

Tamoxifen use in the treatment of breast cancer was associated with greater risks for endometrial cancer, hyperplasia and polyps, as well as other uterine cancers among premenopausal women in Korea, according to study data.

A greater number of live births causally reduced the risk for endometrial cancer, according to study results published in BMC Medicine.

Compared with young women in the general population, those with a cancer diagnosis were more likely to report sexual dysfunction, according to a population-based, cross-sectional study.

The COVID-19 pandemic disrupted treatment for gynecologic cancer patients worldwide and caused disease progression and death, according to a prospective cohort study in American Journal of Obstetrics & Gynecology.

Risks for severe maternal morbidity and mortality appeared higher among pregnancies complicated by cancer, according to study results in a research letter published in JAMA Oncology.

Women with recurrent ovarian cancer experience an average of 14 disease or treatment-related symptoms at any given time over the course of their disease.

CHICAGO — Intermittent relacorilant plus nab-paclitaxel demonstrated an OS benefit among women with recurrent platinum-resistant/refractory ovarian cancer compared with nab-paclitaxel alone.

CHICAGO — Rucaparib monotherapy significantly prolonged PFS compared with placebo in the first-line maintenance setting among women with advanced ovarian cancer, regardless of BRCA mutation and homologous recombination deficiency status.

CHICAGO — The keynote speaker at ASCO Annual Meeting urged attendees to focus on social and organizational innovations that can advance equity in cancer care.

Women demonstrated a 34% increased risk for severe adverse events from any cancer treatment compared with men, according to a study published in Journal of Clinical Oncology.